Bristol comes out swinging at Lilly clot drug
NEW YORK (Reuters) - Bristol-Myers Squibb Co, which sells leading blood clot preventer Plavix, on Thursday dismissed Eli Lilly and Co's rival Effient drug as a "niche" product that has harmed or failed to help three groups of patients in a big study.
<p>You are not allowed to view links.
Register or
Login![](http://feeds.feedburner.com/~a/reuters/healthNews?i=6tQlaY" border="0)
</img>
</p><div class="feedflare">
You are not allowed to view links.
Register or
Login![](http://feeds.feedburner.com/~f/reuters/healthNews?i=yahnXJ" border="0)
</img>
You are not allowed to view links.
Register or
Login![](http://feeds.feedburner.com/~f/reuters/healthNews?i=BiMBtj" border="0)
</img>
You are not allowed to view links.
Register or
Login![](http://feeds.feedburner.com/~f/reuters/healthNews?i=S7yKuj" border="0)
</img>
</div>
![](http://feeds.feedburner.com/~r/reuters/healthNews/~4/345018132" height="1" width="1)
You are not allowed to view links.
Register or
Login
